Cell Res:曹雪涛院士亮点推荐了一项癌症新成果

2015-12-29 佚名 生物通

12月25日,曹雪涛院士在nature子刊Cell Research杂志上发表了一篇题为“Organotropic metastasis: role of tumor exosomes”的文章,为我们亮点推荐了近期发布在《自然》(Nature)杂志上的一项癌症新成果。在这篇文章中,来自美国Meyer癌症中心的研究人员证实表达独特整合素(integrins)的肿瘤外泌体(exosome)可通过它们的

12月25日,曹雪涛院士在nature子刊Cell Research杂志上发表了一篇题为“Organotropic metastasis: role of tumor exosomes”的文章,为我们亮点推荐了近期发布在《自然》(Nature)杂志上的一项癌症新成果。在这篇文章中,来自美国Meyer癌症中心的研究人员证实表达独特整合素(integrins)的肿瘤外泌体(exosome)可通过它们的整合素介导与器官特异性定居细胞融合来准备转移前微环境,由此决定了器官性特异性癌症转移。

肿瘤转移是肿瘤恶性进展至关重要的一步,与大多数癌症治疗失败有关。癌症转移的一个显特点就是,在一些细胞及分子程序的控制下,某些类型的癌细胞优先定植及转移至特异器官处。当前许多的研究都主要将焦点放在鉴别这种器官特异性癌症转移的细胞内在决定因素上,包括癌细胞表达的基因和趋化因子受体。一些粘附及胞外基质分子,如整合素、细胞粘合素(tenascin)和骨膜蛋白(periostin)也被证实促进了转移癌细胞定植。

2005年,Lyden博士和同事们提出了一个叫做“转移前微环境”的术语来描述原发肿瘤可通过招募骨髓源性细胞到远端器官处,建立支持性的转移微环境来促进自身转移。此外,也有研究报道肿瘤源性可溶因子如赖氨酰氧化酶(lysyl oxidase)通过在某些位点形成转移前微环境诱导器官特异性转移。但目前对于器官特异性癌症转移的机制仍然不是很清楚。

近年来,有研究证实肿瘤源性外泌体促进了癌症进展。外泌体是包含着一些功能生物分子(包括蛋白质、RNA、DNA和脂质)的有膜结构的小囊泡,它们可以将这些生物分子水平传递给接受细胞。例如,脑星形胶质细胞源性外泌体可以通过将靶向PTEN的microRNA-19a传递给这些癌细胞来促进脑转移癌细胞生长。尽管如此,对于肿瘤外泌体上的一些分子是否决定了器官特异性转移仍是个待解的问题。

在这篇Nature文章中Lyden和同事们给出了答案,证实肿瘤外泌体整合素可通过与器官特异性定居细胞融合来建立转移前微环境,决定器官特异性癌症转移。他们从已知主要转移至肺、肝和脑器官处的小鼠和人类乳腺癌胰腺癌细胞系中分离出了外泌体,证实它们优先与预计目的地的定居细胞,即肺成纤维细胞与上皮细胞、肝枯否细胞(Kupffer cell)和脑内皮细胞融合。

器官特异性细胞摄取肿瘤源性的外泌体从而准备好转移前微环境。研究人员证实用来自肺转移倾向肿瘤的外泌体进行处理,可以让有骨转移倾向的肿瘤细胞转移重定向。外泌体蛋白质组揭示出了不同的整合素表达模式:外泌体整合素α6β4和α6β1与肺转移相关,外泌体整合素αvβ5与肝转移相关。靶向整合素α6β4和αvβ5可以减少外泌体摄取,并分别抑制肺转移和肝转移。Lyden和同事们还证实定居细胞摄取外泌体整合素激活了Src磷酸化和促炎症S100基因表达。他们的临床数据表明可以利用外泌体整合素来预测器官特异性癌转移。

在文章的最后,曹雪涛院士指出Lyden和同事们的这项研究扩展了我们对于器官特异性癌症转移一机制的认识,也突出强调了外泌体在促进肿瘤转移中至关重要的作用。

原始出处:

A recent paper in Nature shows that tumor exosomes expressing unique integrins can determine organotropic metastasis by preparing pre-metastatic niche through their integrins-mediated fusion with and fertilization of organ-specific resident cells.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-11-20 wgx306
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2016-08-09 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-31 kxzr

    肿瘤研究新方向

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-30 andruhn

    这才是高质量的研究!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-30 1de14ca4m57(暂无匿称)

    看不懂

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-29 dhzzm

    希望有更多的依据支持

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-29 xyfg98

    赞一个

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1922149, encodeId=c8511922149e9, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Nov 20 00:43:00 CST 2016, time=2016-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869273, encodeId=809118692e383, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Feb 06 14:43:00 CST 2016, time=2016-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959529, encodeId=f26a195952907, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Tue Aug 09 06:43:00 CST 2016, time=2016-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50734, encodeId=2b6e50e34c6, content=肿瘤研究新方向, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52661675198, createdName=kxzr, createdTime=Thu Dec 31 08:38:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1351445, encodeId=bf7713514459f, content=<a href='/topic/show?id=c6e06030207' target=_blank style='color:#2F92EE;'>#曹雪涛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60302, encryptionId=c6e06030207, topicName=曹雪涛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Dec 31 07:43:00 CST 2015, time=2015-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50581, encodeId=07db5058180, content=这才是高质量的研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69b61619007, createdName=andruhn, createdTime=Wed Dec 30 17:35:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50386, encodeId=8d0d503864d, content=看不懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d0911672410, createdName=1de14ca4m57(暂无匿称), createdTime=Wed Dec 30 12:22:00 CST 2015, time=2015-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50348, encodeId=73b25034878, content=希望有更多的依据支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Tue Dec 29 21:52:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50339, encodeId=dcf8503390d, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Tue Dec 29 21:14:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=50323, encodeId=f5e05032386, content=牛, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c10c75714, createdName=zhuzhuba1, createdTime=Tue Dec 29 19:23:00 CST 2015, time=2015-12-29, status=1, ipAttribution=)]
    2015-12-29 zhuzhuba1

    0

相关资讯

JAMA:拥有带薪病假可能有助于减轻癌症患者的经济压力

罹患癌症不仅会给患者带来巨大的健康问题和心理压力,也会增加患者的经济压力。为了治疗癌症,许多患者不得不失去就业机会。但是一项新的研究表明,若癌症获得带薪病假,则可减轻患者的经济负担。 这项研究发表在JAMA,研究发现,拥有带薪病假的癌症患者相比那些没有带薪病假的癌症患者而言治疗后更易获得就业机会,且经济压力更小。 目前,在美国约40%的员工未获得带薪病假。因为它并非医疗法案的强制性决策。密歇根大学

Nat Nanotechnol:一种植物病毒---豇豆病毒可有效对抗癌症

最近,美国凯斯西储大学和达特茅斯大学的研究人员报道称,一种常见的植物病毒的外壳,吸入肺部肿瘤或注射到卵巢癌、结肠癌或乳腺肿瘤中,不仅能引发小鼠免疫系统来消灭肿瘤,而且还提供了全身性保护来对抗肿瘤转移。科学家们测试了一个有着100年历史的构想——叫做“原位免疫”(in-situ vaccination)。这个想法是,在肿瘤中放某些东西,破坏可抑制免疫系统的环境,从而让自然防御系统来攻击恶性肿瘤。放入

癌症到底有没有理想标志物?

这是投入最为广泛、最为壮烈的一场全民战争。然而,结果如何呢?据统计,世界恶性肿瘤的发病率和死亡率不但没有明显下降,数种肿瘤反而出现明显上升。 回顾一百年来肿瘤研究的主要目的,大家均是在寻找罹患癌症的证据(或称肿瘤标志物)。临床医生在患者体内找肿块,病理医生在组织中找癌细胞,检验医生在体液中找肿瘤分子,分子生物学工作者在肿瘤细胞中找癌基因……虽然角度不同,层次不同,但根本目的一样,旨在阐明或证

Cell:癌症分子广泛突变的背后秘密---染色体碎裂

自从科学家们开始测序癌细胞基因组,他们注意到了一种奇怪的模式。在许多不同类型的癌症中,细胞内某条染色体的一部分看起来好像被粉碎以后,再错误地拼合到了一起,导致了多种突变。多年来,这一现象一直让科学家们感到困惑。来自洛克菲勒大学的一项新研究为作为癌症前兆的这种奇怪的分子爆炸提供了一种解释。 该研究的领导者、细胞生物学和遗传学实验室主任及教授Titia de Lange说:“‘老’的癌症观点

Nature:癌症生物学机制新突破---基因绝缘子突变

来自Broad研究所(Broad Institute of MIT and Harvard)和麻省总医院(Massachusetts General Hospital and Harvard Medical School)的研究人员揭示了一个全新的癌症生物学机制----一向被称为管家基因异柠檬酸脱氢酶(IDH)突变后,能使两个原本完全不相关的基因发生关联并激活。这项发现揭示了在基因组中,存在一类称

2015年癌症诊断新技术盘点,液体活检,外泌体等上榜

一直以来,癌症的诊断研究领域都是学者们关注的重点,近年来随着研究的深入,许多新型的癌症检测技术不断涌现,比如癌症液体活检技术、microRNA检测工具、成像追踪技术等,本文就盘点了2015年癌症诊断领域的研究亮点。 癌症血液检测新技术 虽然实体肿瘤的检测仍然是癌症诊断中的常规程序,但新一代测序等现代技术,已经使科学家们能够更详细地跟踪肿瘤的组织起源。许多肿瘤脱落的细胞中存在称为外泌体(